Pharmacology and Therapeutics: Recent submissions

Now showing items 1-3 of 399

    • BCL-XL is an actionable target for treatment of malignant pleural mesothelioma 

      Arulananda, S; O’Brien, M; Evangelista, M; Harris, TJ; Steinohrt, NS; Jenkins, LJ; Walkiewicz, M; O’Donoghue, RJJ; Poh, AR; Thapa, B; ... (Springer Science and Business Media LLC, 2020-12-01)
      <jats:title>Abstract</jats:title> <jats:p>Despite having one of the lowest survival rates of all cancers, there have been no new approved treatments for malignant pleural mesothelioma (MPM) in over a decade. Standard-of-care ...

    • STING-Mediated Autophagy Is Protective against H2O2-Induced Cell Death 

      Abdullah, A; Mobilio, F; Crack, PJ; Taylor, JM (MDPI, 2020-10-01)
      Stimulator of interferon genes (STING)-mediated type-I interferon signaling is a well characterized instigator of the innate immune response following bacterial or viral infections in the periphery. Emerging evidence has ...

    • Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination 

      Veit, G; Roldan, A; Hancock, MA; Da Fonte, DF; Xu, H; Hussein, M; Frenkiel, S; Matouk, E; Velkov, T; Lukacs, GL (AMER SOC CLINICAL INVESTIGATION INC, 2020-09-17)
      Based on its clinical benefits, Trikafta - the combination of folding correctors VX-661 (tezacaftor), VX-445 (elexacaftor), and the gating potentiator VX-770 (ivacaftor) - was FDA approved for treatment of patients with ...